Using MRD Status a Endpoint for Drug Approval
Using MRD Status a Endpoint for Drug Approval image
Feb 24, 2022 / 07:00PM - 08:00PM EST
Minimal Residual Disease (MRD) Chapter

Event Description

While more myeloma specialists are accepting the importance of testing for minimal residual disease (MRD), it's harder to agree on what to do with those test results. One of the questions yet to answer is whether or not MRD results should be used as an endpoint on clinical trials.

Listen to Dr. Manni Mohyuddin as he shares his opinion on the subject. This kind of myeloma research can get us quicker to a cure!

Schedule & Agenda

person
Introduction
07:00PM
Audrey Burton-Bethke
Audrey introduces the agenda of the event and featured speaker Dr. Manni Mohyuddin.
person
Presentation
07:05PM
Dr. Manni Mohyuddin, MD
Dr. Manni Mohyuddin shares his opinion minimal residual disease (MRD) testing and what to do with the results. 
person
Questions and Answers
07:35PM
Audience
Type your questions in the chat and we will answer them!

Speakers & Moderators

The panelist Audrey Burton-Bethke
Audrey Burton-Bethke

Audrey joined the HealthTree Foundation as the Myeloma Community Program Director in 2020. While not knowing much about myeloma at the start, she has since worked hard to educate herself, empathize and learn from others' experiences. She loves this job. Audrey is passionate about serving others, loves learning, and enjoys a nice mug of hot chocolate no matter the weather.

Read Bio
The panelist Ghulam (Manni) Mohyuddin, MD
Ghulam (Manni) Mohyuddin, MD

Dr. Mohyuddin completed his medical training at the prestigious Aga Khan University in Pakistan. He completed his internal medicine residency at the University of Kansas where he developed a passion for medical education and treating hematological malignancies. After residency, he pursued Chief Residency at the University of Kansas, focusing on mechanisms of novel educational delivery and improving access to research for trainees. He completed his fellowship at the University of Kansas, developing a clinical and research interest in multiple myeloma, drug repurposing, quality of scientific methods, end of life, cost-effective/evidence-based care and medical education. He enjoys the outdoors tremendously, and that drew him to life in Utah where he is currently an Assistant Professor at the Huntsman Cancer Institute with a focus on multiple myeloma.

Read Bio

Have Any Questions?

Thank you for your interest in the event. If you have any questions, we would love to help!

Feel free to give us a call or send us a message below.

support

Get In Touch With Us

phone

+1 800 709 1113

email

Support@healthtree.org

Get the latest thought leadership on Myeloma delivered straight to your inbox.

Subscribe to the weekly "HealthTree Community for Myeloma Newsletter" for Myeloma news, life with Myeloma stories, Myeloma clinical trials, Myeloma 101 articles and events with Myeloma experts.

Thanks to our HealthTree Community for Myeloma Sponsors:

Legend Biotechnologies
Bristol Myers Squibb
Abbvie
Genentech
GSK
Janssen Oncology

Follow Us

facebook instagram twitter youtube

Copyright © 2022 HealthTree Foundation. All Rights Reserved.

The HealthTree Foundation for Multiple Myeloma (formerly know as Myeloma Crowd) is a qualified 501(c)(3) tax-exempt organization. Tax ID 45-5354811

 https://www.guidestar.org/profile/45-5354811